Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis - PubMed
4 hours ago
- #myasthenia-gravis
- #efgartigimod
- #real-world-evidence
- Efgartigimod (Vyvgart) is used for managing myasthenia gravis (MG), but real-world data on flexible dosing and concomitant medication use is limited.
- A single-center retrospective study evaluated efgartigimod's effectiveness, dosing intervals, and associations with immunosuppressants in MG patients.
- Nine patients (mean age 64 ± 18.1 years, 55.6% male) showed an average 47-day interval between efgartigimod cycles with high variability.
- MG-ADL scores improved significantly at 60 days, 6 months, and 12 months (p = 0.008, 0.016, 0.031, respectively).
- Higher azathioprine doses correlated with longer efgartigimod intervals, suggesting potential disease stability or clinician comfort with extended cycles.
- Small sample size limits generalizability; findings are preliminary and hypothesis-generating.
- Efgartigimod demonstrated effectiveness under flexible dosing, supporting patient-centered treatment approaches.
- Larger prospective studies are needed to optimize dosing strategies and assess long-term outcomes.